Ве молиме користете го овој идентификатор да го цитирате или поврзете овој запис:
http://hdl.handle.net/20.500.12188/11100| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Battelino, Tadej | en_US |
| dc.contributor.author | Deeb, Larry C | en_US |
| dc.contributor.author | Ekelund, Magnus | en_US |
| dc.contributor.author | Kinduryte, Ona | en_US |
| dc.contributor.author | Klingensmith, Georgeanna J | en_US |
| dc.contributor.author | Kocova, Mirjana | en_US |
| dc.contributor.author | Kovarenko, Margarita | en_US |
| dc.contributor.author | Shehadeh, Naim | en_US |
| dc.date.accessioned | 2021-03-22T07:57:55Z | - |
| dc.date.available | 2021-03-22T07:57:55Z | - |
| dc.date.issued | 2018 | - |
| dc.identifier.uri | http://hdl.handle.net/20.500.12188/11100 | - |
| dc.description.abstract | Insulin degludec/insulin aspart (IDegAsp) is a fixed soluble co-formulation of basal and bolus insulin. | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Wiley Online Library | en_US |
| dc.relation.ispartof | Pediatric Diabetes | en_US |
| dc.title | Efficacy and safety of a fixed combination of insulin degludec/insulin aspart in children and adolescents with type 1 diabetes: A randomized trial | en_US |
| dc.type | Article | en_US |
| dc.identifier.doi | 10.1111/pedi.12724 | - |
| dc.identifier.volume | 19 | - |
| dc.identifier.issue | 7 | - |
| item.fulltext | No Fulltext | - |
| item.grantfulltext | none | - |
| crisitem.author.dept | Faculty of Medicine | - |
| Appears in Collections: | Faculty of Medicine: Journal Articles | |
Записите во DSpace се заштитени со авторски права, со сите права задржани, освен ако не е поинаку наведено.